Memo Therapeutics raises $27.7 million to develop antibody treatment : vimarsana.com

The Swiss biotech company Memo Therapeutics (MTx) has bagged CHF 25 million ($27.7 million) in a Series C round to finish the phase 2 development of its lead antibody treatment.

Related Keywords

Japan , Japanese , Pureos Bioventures , Veronica Gambillara Fonck , Drug Administration , Vesalius Biocapital , Fast Track , Vera Therapeutics , Bio Developments , Arkets Amp Regulations , Ipelines , Ntibody Drug Conjugates , Eriesc Funding , Hase 2 , Ntibody , Ipeline , Iral Infection ,